Conversion of tolerogenic CD4-8- dendritic cells to immunogenic ones inducing efficient antitumor immunity

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 1, 2006, Pages 74-80

  Zhang, Xueshu ^a,c   Moyana, Terence ^b   Quereshi, Mabood ^a   Xiang, Jim ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c Saskatoon Cancer Center   (Canada)

Author keywords

Antigen dose; Conversion; Culturing time; DC subset; Tolerance

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; OVALBUMIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DIFFERENTIATION; MELANOMA B16; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH1 CELL; TRANSGENIC MOUSE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; LYMPHOMA, T-CELL; MELANOMA, EXPERIMENTAL; MICE; SPLEEN;

EID: 33644897569     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.74     Document Type: Article

References (31)

1. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296.
2. Jonuleit, H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T-cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213.
3. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233.
4. + regulatory T-cells in vivo in humans. Blood 2002;100:174.
5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245.
6. Pulendran B. Modulating vaccine responses with dendritic cells and toll-like receptors. Immunol Rev 2004;199:227.
7. Shortman K, Liu YJ. Mouse and human dendritic cell subsets. Nat Rev Immunol 2002;2:151.
8. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000;1:199.
9. McLellan AD, Kapp M, Eggert A, et al. Anatomic location and T-cell stimulatory functions of mouse dendritic cell subsets defined by CD4 and CD8 expression. Blood 2002;99:2084.
10. + dendritic cells. J Immunol 2001;166:5327.
11. Legge KL, Gregg RK, Maldonado-Lopez R, et al. On the role of dendritic cells in peripheral T-cell tolerance and modulation of autoimmunity. J Exp Med 2002;196:217.
12. + dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002;196:1099.
13. Girolomoni G, Simon JC, Bergstresser PR, et al. Freshly isolated spleen dendritic cells and epidermal Langerhans cells undergo similar phenotypic and functional changes during short-term culture. J Immunol 1990;145:2820.
14. Girolomoni G, Zambruno G, Manca V, et al. Spleen dendritic cells exhibit altered morphology and increased allostimulatory capacity after short-term culture. Exp Dermatol 1992;1:129.
15. Garrigan K, Moroni-Rawson P, McMurray C, et al. Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors. Blood 1996;88:3508.
16. Edwards AD, Diebold SS, Slack EM, et al. Toll-like receptor expression in murine DC subsets: Lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 2003;33:827.
17. Edwards AD, Manickasingham SP, Sporri R, et al. Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol 2002;169:3652.
18. Boonstra A, Asselin-Paturel C, Gilliet M, et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T-helper type 1 and 2 cell development: Dependency on antigen dose and differential toll-like receptor ligation. J Exp Med 2003;197:101.
19. + T-regulatory 1 cells to suppress antitumor immunity. J Immunol 2005;175:2931.
20. + T-helper-antigen presenting cells. J Immunol 2005;174:7497.
21. Li M, Davey GM, Sutherland RM, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001;166:6099.
22. Livingstone AM, Kuhn M. Dendritic cells need T-cell help to prime cytotoxic T-cell responses to strong antigens. Eur J Immunol 1999;29:2826.
23. Chen Z, Moyana T, Saxena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001;93:539.
24. Liu Y, Bi X, Xu S, et al. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses. Cancer Res 2005;65:1.
25. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: Impact on priming of TH1, TH2, and nonpolarized T-cells. Nat Immunol 2000;1:311.
26. Suzuki Y, Wakita D, Chamoto K, et al. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res 2004;64:8754.
27. Vicari AP, Chiodoni C, Vaure C, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002;196:541.
28. Guiducci C, Vicari AP, Sangaletti S, et al. Redirecting in vivo elicited tumor-infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005;65:3437.
29. Camporeale A, Boni A, Iezzi G, et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T-lymphocytes. Cancer Res 2003;63:3688.
30. Watanabe S, Kagamu H, Yoshizawa H, et al. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity. J Immunol 2003;171:5828.
31. Liu Y, Xia D, Li F, et al. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther 2005;12:122.